# US 2019/0317094 A1 · Zika Virus Assay Systems

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0317094 A1
- Document ID: US20190317094A1
- Status: Published application
- Kind: A1
- Application number: 16/441,388
- Filed: 2019-06-14
- Published: 2019-10-17
- Earliest claimed: 2016-10-29
- Assignees: University of Miami
- Applicants: University of Miami
- Inventors: Sylvia Daunert; Sapna K. Deo; Emre Dikici; Marcello Mascini Mascini; Devon Pawley
- Web page: https://patentgrep.com/patent/US20190317094A1

## CPC

- G01N 33/56983: {Viruses}
- G01N 33/54388: {based on lateral flow}
- G01N 2333/185: Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
- G01N 2469/10: Detection of antigens from microorganism in sample from host
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are Zika virus (ZIKV) binding constructs, e.g., antibodies and antigen-binding fragments thereof and antibody mimetics, as well as related conjugates, polypeptides, nucleic acids, expression vectors, host cells, kits, and assay systems. Methods detecting ZIKV infection and/or ZIKV exposure and/or ZIKV immunity are provided.

## Claims

### Claim 1

An assay system comprising a porous matrix comprising at least three zones, Zone A, Zone B, and Zone C, wherein
Zone A comprises a binding construct that binds to a Zika virus (ZIKV) protein and does not bind to a Dengue virus (DENV) protein, wherein the binding construct is not bound to a Zika virus,
Zone B comprises a binding construct that binds to a ZIKV protein and does not bind to a DENV protein, wherein the binding construct is bound to a Zika virus, and
Zone C comprises a secondary antibody which binds the binding construct of Zone A and Zone B.

### Claim 2 (depends on 1)

The assay system of claim 1, wherein (A) the porous matrix comprises nitrocellulose of polyvinylidene fluoride (PVDF); (B) Zones A to C are arranged along a horizontal axis, wherein each of Zones A to C is flanked by an intervening zone of the porous matrix lacking the binding construct; (C) the method further comprises a sample application pad, a particle conjugate zone, a wick, and/or a backing; or (D) a combination thereof.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5 (depends on 2)

The assay system of claim 2, part (C), wherein the porous matrix, the sample application pad, the particle conjugate zone, and the wick are arranged along a horizontal axis, optionally, wherein the horizontal axis is the same as the horizontal axis along which Zones A to C are arranged, optionally, arranged such that the sample application pad and the wick are located at opposite ends of the assay system along the horizontal axis, wherein the particle conjugate zone is flanked by the sample application pad and the porous matrix and the porous matrix is flanked by the particle conjugate and the wick.

### Claim 6

(canceled)

### Claim 7 (depends on 2)

The assay system of claim 2, part (C), wherein (A) the backing is positioned below the porous matrix, the sample application pad, the particle conjugate zone, and the wick; (B) the particle conjugate zone is bound to a conjugate comprising a binding construct that binds to a Zika virus (ZIKV) protein and does not bind to a Dengue virus (DENV) protein, bound to an element or polymer, optionally, wherein the element is a gold particle or the polymer is polystyrene; (C) the sample application Dad comprises cellulose or glass fiber; (D) the wick comprises nitrocellulose; (E) each of Zone A and Zone B is bound to a binding construct.

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The assay system of claim 1, wherein the binding construct does not bind to a protein of any one of DENV subtype 1, DENV subtype 2, DENV subtype 3, and DENV subtype 4, optionally, wherein the binding construct does not bind to any flavivirus other than ZIKV.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The assay system of claim 1, wherein (A) the ZIKV protein is from a ZIKV comprising the genome of GenBank Accession No. KU926309.1 (SEQ ID NO: 4); (B) the binding construct is an antibody mimetic, optionally, a clamp peptide; (C) the binding construct comprises the structure A1-B-A2 wherein A1 is a first peptide arm that binds to a first binding site of a target protein, A2 is a second peptide arm that binds to a second binding site of the target protein, and B is a bridge peptide which links A1 to A2, optionally, wherein the bridge peptide is about 5 to about 10 amino acids in length, further optionally, wherein (a) A comprises an amino acid sequence of any one of SEQ ID NOs: 24-31, (b) A2 comprises an amino acid sequence of any one of SEQ ID NOs: 16-23, or (c) a combination thereof.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20 (depends on 15)

The assay system of claim 15, part (C), wherein A1 comprises an amino acid sequence of SEQ ID NO: 26 and A2 comprises an amino acid sequence of SEQ ID NO: 18 or A comprises an amino acid sequence of SEQ ID NO: 25 and A2 comprises an amino acid sequence of SEQ ID NO: 21 or A1 comprises an amino acid sequence of SEQ ID NO: 26 and A2 comprises an amino acid sequence of SEQ ID NO: 23.

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23 (depends on 15)

The assay system of claim 15, part (C), wherein (A) the bridge peptide comprises the amino acid sequence of SEQ ID NO: 32, (B) the binding construct comprises an amino acid sequence of SEQ ID NO: 10, 13, or 14, or (C) a combination thereof.

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

A binding construct comprising the structure A1-B-A2 wherein A1 is a first peptide arm that binds to a first binding site of a target protein, A2 is a second peptide arm that binds to a second binding site of the target protein, and B is a bridge peptide which links A1 to A2, optionally, wherein the bridge peptide is about 5 to about 10 amino acids in length.

### Claim 27

(canceled)

### Claim 28 (depends on 26)

The binding construct of claim 26, wherein (a) A1 comprises an amino acid sequence of any one of SEQ ID NOs: 24-31, (b) A2 comprises an amino acid sequence of any one of SEQ ID NOs: 16-23, or (c) a combination thereof, optionally, wherein A1 comprises an amino acid sequence of SEQ ID NO: 26 and A2 comprises an amino acid sequence of SEQ ID NO: 18 or A1 comprises an amino acid sequence of SEQ ID NO: 25 and A2 comprises an amino acid sequence of SEQ ID NO: 21 or A1 comprises an amino acid sequence of SEQ ID NO: 26 and A2 comprises an amino acid sequence of SEQ ID NO: 23.

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32 (depends on 26)

The binding construct of claim 26, wherein the bridge peptide comprises the amino acid sequence of SEQ ID NO: 32 or the binding construct comprises an amino acid sequence of SEQ ID NO: 10, 13, or 14.

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37 (depends on 1)

A method of detecting a Zika virus (ZIKV) infection and ZIKV immunity in a subject, comprising adding a sample obtained from a subject to the assay system according to claim 1, wherein, when the assay system exhibits a single band in Zone C, the subject is determined as having neither a ZIKV infection nor ZIKV immunity, when the assay system exhibits a band in each of Zone A and Zone B, the subject is determined as having both a ZIKV infection and ZIKV immunity, and when the assay system exhibits a band in Zone B and a band is absent in Zone A, the subject is determined as not having a ZIKV infection but having ZIKV immunity.

### Claim at position 38

-50. (canceled)
